

Impact of metabolically healthy obesity on the risk of incident gastric cancer: a population-based cohort study

Yoshitaka Hashimoto

Kyoto Prefectural University of medicine <https://orcid.org/0000-0002-8794-0550>

Masahide Hamaguchi (✉ mhama@koto.kpu-m.ac.jp)

<https://orcid.org/0000-0002-8651-4445>

Akihiro Obora

Asahi University Hospital

Takao Kojima

Asahi University Hospital

Michiaki Fukui

Kyoto Prefetural University of Medicine

Research article

Keywords: Obesity; Metabolically healthy obesity; Metabolic syndrome; Cancer; Gastric cancer.

Posted Date: December 11th, 2019

DOI: <https://doi.org/10.21203/rs.2.10798/v3>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on January 20th, 2020. See the published version at <https://doi.org/10.1186/s12902-019-0472-2>.

Abstract

Background The risk of colon or breast cancer in metabolically healthy obese (MHO) were lower than that in metabolically abnormal obese (MAO). We hypothesized that the risk of incident gastric cancer in MHO is lower than that in MAO.

Methods This historical cohort study included 19,685 Japanese individuals who received health-checkup programs from 2003 to 2016. Each subject was classified as metabolically healthy (MH) (no metabolic abnormalities) or metabolically abnormal (MA) (one or more metabolic abnormalities), according to four metabolic factors (hypertension, impaired fasting glucose, hypertriglyceridemia and low HDL-cholesterol). Obese (O) or non-obese (NO) was classified by a BMI cutoff of 25.0 kg/m². Hazard ratios of metabolic phenotypes for incident gastric cancer were calculated by the Cox proportional hazard model with adjustments for age, sex, alcohol consumption, smoking and exercise.

Results Over the median follow-up period of 5.5 (2.9-9.4) years, incident rate of gastric cancer was 0.65 per 1000 persons-years. Incident rate of MHNO, MHO, MANO and MAO were 0.33, 0.25, 0.80 and 1.21 per 1000 persons-years, respectively. Compared with MHNO, the adjusted hazard ratios for development of gastric cancer were 0.69 (95%CI 0.04–3.39, $p = 0.723$) in MHO, 1.16 (95%CI 0.63–2.12, $p = 0.636$) in MANO and 2.09 (95%CI 1.10–3.97, $p = 0.024$) in MAO.

Conclusions This study shows that individuals with MAO, but not those with MHO, had an elevated risk for incident gastric cancer. Thus, we should focus more on the presence of metabolic abnormalities rather than obesity itself for incident gastric cancer.

1. Background

Gastric cancer is a major global health concern and was the third leading cause of cancer death worldwide in 2012 [1] and gastric cancer is the third leading cause of cancer death in 2016 in Japan [2]. Previous meta-analyses showed that obesity was a risk factor for incident gastric cancer, especially gastric cardia cancer [3], although an umbrella review revealed the effect of obesity on gastric cancer was smaller than that on other obesity-related cancers, such as colon and breast cancers [4].

On the other hand, obesity is also known as a risk factor for type 2 diabetes mellitus (T2DM) [5], chronic kidney disease (CKD) [6] and cardiovascular disease (CVD) [7]. The subgroup of individuals with metabolically healthy obesity (MHO)—i.e., obesity without metabolic abnormalities—are known as lower risk of T2DM, CKD and CVD than individuals with metabolic abnormalities obese [8-11]. However, these studies also revealed that individuals with the MHO phenotype were at higher risk of T2DM, CKD and CVD than individuals with metabolically healthy non-obese [8,10,11]. In addition, there is accumulating evidence that metabolically abnormal obesity (MAO), but not MHO, confers an elevated risk of incident colon cancer [12] and breast cancer [13]. The association between gastric cancer and obesity among Japanese population is controversial [14,15]. These studies did not consider the presence of metabolic abnormalities. In contrast, there is an association between metabolic syndrome and incidence of gastric

cancer [16-19]. Thus, we thought that not obesity itself, but the presence of metabolic abnormalities, which often accompany with obesity, have an important meaning for gastric cancer.

To our knowledge, however, no previous studies have clarified the relation between MHO and incident gastric cancer. Thus, the aim of this study was to elucidate the impact of MHO on incident gastric cancer.

2. Methods

2.1 Study population

This was an historical cohort study of participants who received a medical health-checkup at Asahi University Hospital (the **NAGALA** (**NA**fld in **Gifu** **A**rea, **L**ongitudinal **A**nalysis) study, Gifu, Japan) [20]. The purpose of medical health-checkup was to promote public health by early detection of chronic diseases and their risk factors and about 60-70% examiners received the examinations, repeatedly; thus, the participants represent apparently healthy individuals. Most of the participants of this medical health-checkup were employees of various companies and local governmental organizations in Gifu, Japan, and their consorts. The medical data of all individuals who agreed to participate in the study were stored in a database after removing all personally identifiable information. For the current study, we used the results of individuals who participated in the health-checkup program for at least one year between 2003 and 2016. The exclusion criteria of this study were as follows: the presence of gastric cancer at baseline examination, missing covariate data (body weight, high-density lipoprotein (HDL) cholesterol, and lifestyle factors) and no follow-up health-checkup programs. Informed consent was obtained from each participant. The study was approved by the ethics committee of Murakami Memorial Hospital and was conducted in accordance with the Declaration of Helsinki.

2.2 Data collection

A self-administered questionnaire was used for gathering the medical history and lifestyle factors of participants [20]. In regard to alcohol consumption, participants were asked the type and amounts of alcoholic beverages consumed per week over the past month, and then the mean ethanol intake per week was estimated [21]. For smoking status, the participants were categorized into three groups: never-, ex- and current smokers. In addition, smoking burden was evaluated by pack-years which were calculated by multiplying the number of cigarette packs smoked per day by the number of years of smoking [22]. For exercise, participants were asked to describe the type, duration and frequency of sports or recreational activities [23]. Based on the results, we defined regular exercisers as the participants who performed any kind of sports activity at least once a week on a regular basis [21]. Body mass index (BMI) (kg/m^2) was calculated as body weight (kg) divided by height (m) squared. Waist circumference was measured as the abdominal circumference around the navel. Fasting plasma glucose, triglycerides, or HDL cholesterol was measured using the venous blood after an overnight fast. The methods for detecting and diagnosing gastrointestinal cancers were described previously [24]. Because the first standardized questionnaires for

gastrointestinal cancers were sent on Jan 1st 2003, we set the study period as Jan 1st 2003 to Dec 31st 2016. The primary endpoint of this study was hazard risk (HR) of MHO for gastric cancer.

2.3 Definitions of metabolic phenotypes

We used body mass index ≥ 25.0 kg/m² to identify the individual with obesity. This value has been proposed as a cutoff for the diagnosis of individual with obesity in Asian people [25] and has often been used in Japan [26,27]. Four metabolic factors (fasting plasma glucose, triglycerides, HDL cholesterol and blood pressure) were used to divide participants into metabolically healthy or metabolically abnormal subgroups [9]. Impaired fasting plasma glucose and/or diabetes was defined as fasting plasma glucose ≥ 5.6 mmol/L and/or current medical treatment. Hypertension was defined as systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg or current medical treatment. Elevated triglycerides were defined as triglycerides ≥ 1.7 mmol/L or treatment for hyperlipidemia. Low HDL-cholesterol was defined as < 1.0 mmol/L in men and < 1.3 mmol/L in women. When none of these four metabolic factors were present, we defined the participants as metabolically healthy (MH) and when one or more of these four metabolic factors were present, we defined the participants as metabolically abnormal (MA) [28]. Then, participants were categorized at the baseline examination into 4 phenotypes: metabolically healthy non-obesity (MHNO), metabolically healthy obesity (MHO); metabolically abnormal non-obesity (MANO), and metabolically abnormal obesity (MAO).

2.4 Statistical analysis

The study participants were divided into four groups based on metabolic phenotypes. Continuous variables were expressed as the means \pm standard deviation or median (interquartile range) and categorical variables were expressed as numbers. The clinical characteristics at baseline examination of the four groups were compared; continuous variables of groups were evaluated by one-way ANOVA and Tukey's Honestly Significant Difference Test or Kruskal-Wallis Test and Steel-Dwass Test, and categorical variables of groups were evaluated by Pearson's Chi-Squared Test. Because of the censored cases and inconsistent follow-up duration, we used the Cox Proportional Hazards Model to calculate the HR of the four groups. We considered five potential confounders as covariates: age, sex, alcohol consumption [29], pack-years [30], and exercise [31]. Because alcohol consumption and pack-years were skewed variables, logarithmic transformation was carried out before performing the Cox Proportional Hazard Model analysis.

Furthermore, we used the Cox Proportional Hazards Model to calculate the HR of each metabolic abnormality (hypertension, impaired fasting glucose, hypertriglyceridemia and low HDL-cholesterol).

The statistical analyses were performed using JMP version 13.2 software (SAS Institute Inc., Cary, NC). A *p* value < 0.05 was considered statistically significant.

3. Results

We included 27,944 participants from the NAGALA database (Figure 1). Among them, 8,259 participants were excluded. Thus, 19,685 participants were eligible for this cohort study. The baseline characteristics of the participants are shown in Table 1. Average age and BMI of this study participants were 45.5 ± 9.5 years old and 22.6 ± 3.3 kg/m² and 59.9% (11,782) were men. In addition, both BMI and metabolic parameters, including blood pressure, fasting plasma glucose, triglycerides and HDL cholesterol, were different among the four metabolic phenotype groups.

Over the median follow-up period of 5.5 (2.9-9.4) years, incident rate of gastric cancer was 0.65 per 1000 persons-years. Incident rate of MHNO, MHO, MANO and MAO were 0.33, 0.25, 0.80 and 1.21 per 1000 persons-years, respectively.

The results of the Cox proportional hazard model are shown in Table 2 and Supplemental Table. Compared with the MHNO phenotype, the MAO phenotype (adjusted HR 2.09, 95%CI 1.10–3.97, $p = 0.024$) was associated with a higher risk for development of gastric cancer after adjusting for covariates, whereas the MHO phenotype (adjusted HR 0.69, 95%CI 0.04–3.39, $p = 0.723$) was not.

Furthermore, presence of impaired fasting plasma glucose and/or diabetes, hypertension and elevated triglycerides were associated with incident gastric cancer (Table 3).

4. Discussion

This cohort study of apparently healthy Japanese people is the first to reveal an association between MHO and incident gastric cancer. This study shows that individuals with MAO, but not those with MHO, had an elevated risk for incident gastric cancer. In addition, the presence of impaired fasting plasma glucose and/or diabetes, and hypertension were associated with elevated risk incident gastric cancer.

Obesity was a risk factor for incident gastric cancer [3], although the effect of obesity on gastric cancer was smaller than that on other obesity-related cancers. Previous studies revealed that the risk of incident colorectal cancer [12] and incident breast cancer [13], both of which have been shown to be related to obesity [4], was not high in subjects with MHO. In addition, another study revealed that the risk of obesity-related cancer in MHO was lower than that in MAO [32]. In fact, previous studies revealed the association between metabolic syndrome and incidence of gastric cancer [16-19].

As to why MAO, but not MHO, was associated with a higher risk of incident gastric cancer, there were several possible explanations. It has been reported that metabolic syndrome is associated with gastric cancer [16-19,33]. In this study, we showed that the presence of metabolic abnormalities, especially impaired fasting plasma glucose and/or diabetes and hypertension, were associated with gastric cancer, which was same as previous studies [34,35]. Inflammation, as represented by elevation of the pro-inflammatory cytokines tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), is known to be closely associated with not only obesity [36], but also the metabolic abnormalities, including impaired fasting plasma glucose and hypertension [37].

Inflammation leads to the development of gastric cancer by stimulating proliferation and inhibiting apoptosis of human gastric cancer cells [38]. Formation of reactive oxygen species (ROS), by formation of advanced glycation end products [39], leads to DNA damage and development of gastric cancer. In addition, tumor cell progression is stimulated by enhancing the mTOR signaling pathways through an increase in insulin-like growth factor 1 (IGF-1) [40]. On the other hand, it has been reported that the levels of inflammation and IGF-1 in MHO were lower than those in MAO [41,42]. Collectively, these results could explain why the MAO phenotype, but not the MHO phenotype, was associated with a higher risk of incident gastric cancer.

Some limitations of our study should be noted. First, there was a possibility of selection bias, because we only included the participants who were re-examined in the health-checkup program. There is a possibility that there is a characteristic difference between the participants who were re-examined in the health-checkup program and those who did not. Second, we did not have data on *H. pylori* infection, which is known to pose a risk for gastric cancer [43]. In fact, many Japanese, especially elderly people, are infected with *H. pylori* [44]. Therefore, the results of this study might have been affected by the status of *H. pylori* infection. Third, we did not have detailed data on gastric cancer according to the anatomic location of the lesion, such as gastric non-cardia cancer and gastric cardia cancer. A previous study revealed that gastric cardia cancer showed a greater association with obesity than non-cardia cancer [1]. Lastly, the generalizability of our study to non-Japanese populations is uncertain.

5. Conclusions

In conclusion, our study showed that MAO individuals, not but MHO individuals, had a higher risk of incident gastric cancer. Thus, to prevent future gastric cancer, we should focus more on the presence of metabolic abnormalities rather than obesity itself.

List Of Abbreviations

BMI, body mass index

CVD, cardiovascular disease

CKD, chronic kidney disease

HDL, high-density lipoprotein

HR, hazard ratio

IGF-1, insulin-like growth factor 1

IL-6, interleukin-6

MANO, metabolically abnormal non-obesity

MAO, metabolically abnormal obesity

MCP-1, monocyte chemoattractant protein-1

MHNO, metabolically healthy non-obesity

MHO, metabolically healthy obesity

ROS, reactive oxygen species

T2DM, type 2 diabetes mellitus

TNF- α , tumor necrosis factor- α

Declarations

Ethics approval and consent to participate: Written informed consent was obtained from each participant. The study was approved by the ethics committee of Murakami Memorial Hospital.

Consent to publish: Not applicable.

Availability of data and materials: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests: None. Potential conflict of interest was follows; Y.H. received grants from the Japan Society for the Promotion of Science, and Asahi Kasei Pharma outside the submitted work. M.F. received grants from the Japan Society for the Promotion of Science, AstraZeneca Plc, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Company, Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma, Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. The sponsors were not involved in the study design; in the collection, analysis, or interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The above authors declare that although they are affiliated with a department that is supported financially by a pharmaceutical company, they have received no funding for this study, and their affiliation does not alter their adherence to all the journal policies on sharing data and materials. The other authors have nothing to disclose.

Funding: No funding was obtained for this study.

Authors' Contributions: Y.H. designed the study, analyzed and interpreted the data, and wrote the manuscript. M.H. originated the study, researched and interpreted the data, and reviewed and edited the manuscript. A.O. and T.K. originated the study, researched the data and reviewed the manuscript. M.F.

designed the study, interpreted the data, and reviewed the manuscript. M.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors have approved the final draft submitted.

Acknowledgments: We thank all the staff members at the medical health checkup center at Asahi University Hospital.

References

1. Upala S, Jaruvongvanich V, Riangwiwat T, et al. Association between *Helicobacter pylori* infection and metabolic syndrome: a systematic review and meta-analysis. *J Dig Dis* 2016;**17**:433-440 doi: 10.1111/1751-2980.12367
2. Vital Statistics Japan. Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei16/dl/11_h7.pdf Available on 24 Feb, 2018.
3. Lin XJ, Wang CP, Liu XD, et al. Body mass index and risk of gastric cancer: a meta-analysis. *Jpn J Clin Oncol* 2014;**44**:783-791 doi: 10.1093/jjco/hyu082
4. Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. *BMJ* 2017;**356**:j477 doi: 10.1136/bmj.j477
5. Mitsuhashi K, Hashimoto Y, Tanaka M, et al. Combined effect of body mass index and waist-height ratio on incident diabetes; a population based cohort study. *J Clin Biochem Nutr* 2017;**61**:118-122 doi: 10.3164/jcbrn.16-116
6. Garofalo C, Borrelli S, Minutolo R, et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. *Kidney Int* 2017;**91**:1224-1235 doi: 10.1016/j.kint.2016.12.013
7. Arnlöv J, Ingelsson E, Sundström J, et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. *Circulation* 2010;**121**:230-236 doi: 10.1161/CIRCULATIONAHA.109.887521
8. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. *Obes Rev* 2014;**15**:504-515 doi: 10.1111/obr.12157
9. Hashimoto Y, Tanaka M, Okada H, et al. Metabolically Healthy Obesity and Risk of Incident CKD. *Clin J Am Soc Nephrol* 2015;**10**:578-583 doi: 10.2215/CJN.08980914
10. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. *Ann Intern Med* 2013;**159**:758-769 doi: 10.7326/0003-4819-159-11-201312030-00008
11. Zhang J, Jiang H, Chen J. Combined effect of body mass index and metabolic status on the risk of prevalent and incident chronic kidney disease: a systematic review and meta-analysis. *Oncotarget* 2017;**8**:35619-35629 doi: 10.18632/oncotarget.10915
12. Murphy N, Cross AJ, Abubakar M, et al. A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer

- and Nutrition (EPIC). *PLoS Med* 2016;**13**:e1001988 doi: 10.1371/journal.pmed.1001988
13. Park YM, White AJ, Nichols HB, et al. The association between metabolic health, obesity phenotype and the risk of breast cancer. *Int J Cancer* 2017;**140**:2657-2666 doi: 10.1002/ijc.30684
 14. Kuriyama S, Tsubono Y, Hozawa A, et al. Obesity and risk of cancer in Japan. *Int J Cancer* 2005;**113**:148–157 doi:10.1002/ijc.20529
 15. Tanaka T, Nagata C, Oba S, et al. Prospective cohort study of body mass index in adolescence and death from stomach cancer in Japan. *Cancer Sci* 2007;**98**:1785–1789 doi:10.1111/j.1349-7006.2007.00583.x
 16. Li F, Du H, Li S, Liu J. The Association Between Metabolic Syndrome and Gastric Cancer in Chinese. **Front Oncol** 2018;**8**:326 doi:10.3389/fonc.2018.00326
 17. Yoo H, Kim H, Lee JH, et al. Study on the Relevance of Metabolic Syndrome and Incidence of Gastric Cancer in Korea. *Int J Environ Res Public Health* 2019;**16**:1101 doi:10.3390/ijerph16071101
 18. Li Z, Han H, Chang Y. Association between metabolic syndrome and the incidence of gastric cancer: a meta-analysis of cohort studies. *Diabetol Metab Syndr* 2019;**11**:83 doi:10.1186/s13098-019-0478-y
 19. Lin Y, Ness-Jensen E, Hveem K, et al. Metabolic syndrome and esophageal and gastric cancer. *Cancer Causes Control* 2015;**26**:1825–1834 doi:10.1007/s10552-015-0675-4.
 20. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. *Ann Intern Med* 2005;**143**:722-728
 21. Hashimoto Y, Hamaguchi M, Nakanishi N, et al. Urinary pH is a predictor of diabetes in men; a population based large scale cohort study. *Diabetes Res Clin Pract* 2017;**130**:9-14 doi: 10.1016/j.diabres.2017.04.023
 22. Cigarette smoking and health. American Thoracic Society. *Am J Respir Crit Care Med* 1996;**153**:861-865 doi: 10.1164/ajrccm.153.2.8564146
 23. Aaron DJ, Kriska AM, Dearwater SR, et al. Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activity in adolescents. *Am J Epidemiol* 1995;**142**:191-201
 24. Hamaguchi M, Hashimoto Y, Obora A, et al. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study. *BMJ Open Gastroenterol* 2019;**6**:e000295 doi:10.1136/bmjgast-2019-000295
 25. World Health Organization Western Pacific Region, International Association for the Study of Obesity/International Obesity Task Force: The Asia-Pacific Perspective: Redefining Obesity and Its Treatment, Melbourne, Australia, Health Communications Australia, 2000
 26. Okamura T, Hashimoto Y, Hamaguchi M, et al. Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: a population-based longitudinal study. *Int J Obes (Lond)* 2019;**43**:139-148 doi: 10.1038/s41366-018-0076-3
 27. Hashimoto Y, Hamaguchi M, Tanaka M, et al. Metabolically healthy obesity without fatty liver and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. *Obes Res Clin Pract*

- 2018;**12**:4-15 doi: 10.1016/j.orcp.2017.12.003
28. Heianza Y, Kato K, Kodama S, et al. Stability and changes in metabolically healthy overweight or obesity and risk of future diabetes: Niigata wellness study. *Obesity (Silver Spring)* 2014;**22**:2420-2425 doi: 10.1002/oby.20855
29. Tramacere I, Negri E, Pelucchi C, et al. A meta-analysis on alcohol drinking and gastric cancer risk. *Ann Oncol* 2012;**23**:28-36 doi:10.1093/annonc/mdr135
30. Nishino Y, Inoue M, Tsuji I, et al. Tobacco smoking and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. *Jpn J Clin Oncol* 2006;**36**:800-807 doi:10.1093/jjco/hyl112.
31. Abioye AI, Odesanya MO, Abioye AI, et al. Physical activity and risk of gastric cancer: a meta-analysis of observational studies. *Br J Sports Med* 2015;**49**:224-229 doi:10.1136/bjsports-2013-092778
32. Moore LL, Chadid S, Singer MR, et al. Metabolic health reduces risk of obesity-related cancer in framingham study adults. *Cancer Epidemiol Biomarkers Prev* 2014;**23**:2057-2065 doi: 10.1158/1055-9965.EPI-14-0240
33. Lin Y, Ness-Jensen E, Hveem K, et al. Metabolic syndrome and esophageal and gastric cancer. *Cancer Causes Control* 2015;**26**:1825-1834 doi: 10.1007/s10552-015-0675-4
34. Zhang ZF, Kurtz RC, Sun M, et al. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. *Cancer Epidemiol Biomarkers Prev* 1996;**5**:761-768.
35. Yoon JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis. *World J Gastroenterol* 2013;**19**:936-945 doi:10.3748/wjg.v19.i6.936
36. Alemán JO, Eusebi LH, Ricciardiello L, et al. Mechanisms of obesity-induced gastrointestinal neoplasia. *Gastroenterology* 2014;**146**:357-373 doi: 10.1053/j.gastro.2013.11.051
37. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. *Nat Rev Cancer* 2012;**12**:159-169. Published 2012 Feb 16. doi:10.1038/nrc3215
38. Kuroda T, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. *Clin Cancer Res* 2005;**11**:7629-7636 doi: 10.1158/1078-0432.CCR-05-0798
39. Ferder L, Inserra F, Martínez-Maldonado M. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. *Curr Hypertens Rep* 2006;**8**:191-198 doi:10.1007/s11906-006-0050-7
40. Gallagher EJ, LeRoith D. Minireview: IGF, Insulin, and Cancer. *Endocrinology* 2011;**152**:2546-2551 doi: 10.1007/s00125-016-4101-6
41. Bañuls C, Rovira-Llopis S, Lopez-Domenech S, et al. Oxidative and endoplasmic reticulum stress is impaired in leukocytes from metabolically unhealthy vs healthy obese individuals. *Int J Obes* 2017;**41**:1556-1563 doi: 10.1038/ijo.2017.147

42. Sesti G, Succurro E, Arturi F, et al. IGF-1 levels link estimated glomerular filtration rate to insulin resistance in obesity: A study in obese, but metabolically healthy, subjects and obese, insulin-resistant subjects. *Nutr Metab Cardiovasc Dis* 2011;**21**:933-940 doi: 10.1016/j.numecd.2010.02.008
43. Lee YC, Chiang TH, Chou CK, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. *Gastroenterology* 2016;**150**:1113-1124.e5 doi: 10.1053/j.gastro.2016.01.028
44. Inoue M. Changing epidemiology of Helicobacter pylori in Japan. *Gastric Cancer* 2017;**20**:3-7 doi: 10.1007/s10120-016-0658-5

Tables

Table 1. Characteristics of study participants at the baseline examination

	All	MHNO	MHO	MANO	MAO	<i>p</i>
N	19,685	8,331	653	7,276	3,425	—
Age, years (mean ± SD)	45.5 ± 9.5	42.6 ± 8.7	43.8 ± 8.3 *	48.3 ± 9.7 *†	47.0 ± 9.0 *†‡	<0.001
Men, % (n)	59.9% (11,782)	42.0% (3,496)	424/229	5,088/2,188	2,774/651	<0.001
BMI, kg/m ² (mean ± SD)	22.6 ± 3.3	20.7 ± 2.1	26.7 ± 1.7 *	22.1 ± 1.9 *†	27.6 ± 2.5 *†‡	<0.001
Waist circumference, cm (mean ± SD)	78.0 ± 9.6	72.3 ± 7.0	86.9 ± 6.0 *	77.9 ± 6.8 *†	90.6 ± 7.2 *†‡	<0.001
SBP, mmHg (mean ± SD)	117.5 ± 16.3	108.0 ± 10.7	116.1 ± 8.9 *	122.2 ± 16.2 *†	130.8 ± 15.2 *†‡	<0.001
DBP, mmHg (mean ± SD)	73.7 ± 11.2	67.2 ± 7.8	72.6 ± 6.7 *	76.9 ± 11.0 *†	82.6 ± 10.1 *†‡	<0.001
FPG, mmol/L (mean ± SD)	5.4 ± 0.9	5.0 ± 0.3	5.1 ± 0.3 *	5.6 ± 1.0 *†	6.0 ± 1.3 *†‡	<0.001
Triglycerides, mmol/L (median (interquartile range))	0.8 (0.5–1.2)	0.6 (0.4–0.8)	0.8 (0.6–1.2) *	1.0 (0.6–1.5) *†	1.3 (0.9–1.9) *†‡	<0.001
HDL cholesterol, mmol/L (mean ± SD)	1.4 ± 0.4	1.6 ± 0.4	1.4 ± 0.3 *	1.3 ± 0.4 *†	1.2 ± 0.3 *†‡	<0.001
Exercise	1,6111/3,574	81.4% (6,781)	540/113	5,911/1,365	2,879/546	0.002
Smoking status						<0.001
Never- smoker, % (n)	53.2% (10,480)	65.0% (5,414)	53.0% (346)	45.9% (3,342)	40.2% (1,378)	

Ex-smoker, % (n)	22.4% (4,405)	16.0% (1,331)	23.4% (153)	26.1% (1,897)	29.9% (1,024)	
Current smoker, % (n)	24.3% (4,776)	16.5 % (1375)	23.6% (154)	27.9% (2,029)	29.7% (1,018)	
Smoking burden, pack-years (median (interquartile range))	0 (0-305)	0 (0-120)	0 (0-300) *	50 (0-420) *†	150 (0-460) *†‡	<0.001
Alcohol consumption, g/wk (median (interquartile range))	4.2 (0-90)	1 (0-54)	1 (0-66) *	12 (0-126) *†	12 (1-126) *†	0.070

MHNO, Metabolically healthy non-obesity; MHO, Metabolically healthy obesity; MANO, Metabolically abnormal non-obesity; MAO, Metabolically abnormal obesity; BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; FPG, Fasting plasma glucose; HDL, High-density lipoprotein. Data are the % (number), mean \pm standard deviation, or median (interquartile range). The analyses of continuous variables to assess differences among the four groups were performed using one-way ANOVA or Kruskal-Wallis Test, followed by Tukey's Honestly Significant Difference Test or Steel-Dwass Test. The analyses of categorical variables among the four groups were determined by Pearson's Chi-Squared Test. *, $p < 0.05$ vs. MHNO; †, $p < 0.05$ vs. MHO; and ‡, $p < 0.05$ vs. MANO.

Table 2. Hazard ratio of metabolic phenotype for incident gastric cancer

	MHNO	MHO	MANO	MAO
Person-year, n	51846.1	3949.65	44011.9	20583.1
Incident cases, n	17	1	35	25
Incidence rate per 1000 person-years	0.33	0.25	0.80	1.21
Crude model	Ref	0.77 (0.04-3.77), <i>p</i> = 0.797	2.43 (1.38-4.45), <i>p</i> = 0.002	3.72 (2.02-7.00), <i>p</i> < 0.001
Model 1	Ref	0.68 (0.04-3.32), <i>p</i> = 0.691	1.19 (0.66-2.23), <i>p</i> = 0.567	2.16 (1.14-4.09), <i>p</i> = 0.018
Model 2	Ref	0.69 (0.04-3.39), <i>p</i> = 0.723	1.16 (0.63-2.12), <i>p</i> = 0.636	2.09 (1.10-3.97), <i>p</i> = 0.024

MHNO, Metabolically healthy non-obesity; MHO, Metabolically healthy obesity; MANO, Metabolically abnormal non-obesity; MAO, Metabolically abnormal obesity; CI, Confidence interval; Log, logarithmic. Model 1 was adjusted for age and sex. Model 2 was adjusted for age, sex, exercise habit, log (alcohol consumption + 1) and log (pack-year + 1).

Table 3. Hazard ratio of each metabolic phenotype for incident gastric cancer

	Impaired fasting plasma glucose and/or diabetes (-)	Impaired fasting plasma glucose and/or diabetes (+)
Person-year, n	85934.94	34455.79
Incident cases, n	38	40
Incidence rate per 1000 person-years	0.44	1.16
Crude model	Ref	2.67 (1.71-4.17), <i>p</i> <0.001
	Hypertension (-)	Hypertension (+)
Person-year, n	91735.7	28655
Incident cases, n	46	32
Incidence rate per 1000 person-years	0.50	1.12
Crude model	Ref	2.28 (1.44-3.56), <i>p</i> <0.001
	Elevated triglycerides (-)	Elevated triglycerides (+)
Person-year, n	104572	15818.4
Incident cases, n	62	16
Incidence rate per 1000 person-years	0.59	1.01
Crude model	Ref	1.69 (0.94-2.85), <i>p</i> = 0.077
	Low HDL-cholesterol (-)	Low HDL-cholesterol (+)
Person-year, n	93354.8	27036
Incident cases, n	55	23
Incidence rate per 1000 person-years	0.59	0.86
Crude model	Ref	1.41 (0.85-2.26), <i>p</i> = 0.180

HDL, High-density lipoprotein.

Figures




Figure 1

Inclusion and exclusion flow chart. NAGALA, NAFLD in Gifu Area, Longitudinal Analysis; MHNO, Metabolically healthy non-obesity; MHO, Metabolically healthy obesity; MANO, Metabolically abnormal non-obesity; MAO, Metabolically abnormal obesity.